Cargando…

COVID-19 Antibody Tests: An Overview

Novel coronavirus (nCoV) first emerged in Hubei province of China in December 2019. The virus initially known as 2019-nCoV was renamed to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. The associated disease is known as coronavirus...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravi, Arjun B., Singh, V. P. Prabath, Chandran, Roshni, Venugopal, Krishnan, Haridas, Kaushik, Kavitha, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375937/
https://www.ncbi.nlm.nih.gov/pubmed/34447041
http://dx.doi.org/10.4103/jpbs.JPBS_786_20
_version_ 1783740401495048192
author Ravi, Arjun B.
Singh, V. P. Prabath
Chandran, Roshni
Venugopal, Krishnan
Haridas, Kaushik
Kavitha, R.
author_facet Ravi, Arjun B.
Singh, V. P. Prabath
Chandran, Roshni
Venugopal, Krishnan
Haridas, Kaushik
Kavitha, R.
author_sort Ravi, Arjun B.
collection PubMed
description Novel coronavirus (nCoV) first emerged in Hubei province of China in December 2019. The virus initially known as 2019-nCoV was renamed to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. The associated disease is known as coronavirus disease 2019 (COVID-19). As the COVID-19 pandemic has unfolded, interest has grown in antibody testing as a way to measure how far the infection has spread and to identify individuals who may be immune. Molecular diagnostic tests like polymerase chain reaction are developed rapidly, however they are not able to fulfill all the requirements of an epidemic reaction. Hence, to complement molecular diagnostic tests, serology tests emerged as a vital aspect of the overall response by confirming the presence of antibodies during the early stage of the infection. Antibody tests help in assessing herd immunity, data about the ongoing phase of infection, identifying potential donors for convalescent plasma therapy, etc. This review currently focuses on giving an overview about the antibody tests in SARS-CoV-2 infections.
format Online
Article
Text
id pubmed-8375937
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-83759372021-08-25 COVID-19 Antibody Tests: An Overview Ravi, Arjun B. Singh, V. P. Prabath Chandran, Roshni Venugopal, Krishnan Haridas, Kaushik Kavitha, R. J Pharm Bioallied Sci Review Article Novel coronavirus (nCoV) first emerged in Hubei province of China in December 2019. The virus initially known as 2019-nCoV was renamed to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. The associated disease is known as coronavirus disease 2019 (COVID-19). As the COVID-19 pandemic has unfolded, interest has grown in antibody testing as a way to measure how far the infection has spread and to identify individuals who may be immune. Molecular diagnostic tests like polymerase chain reaction are developed rapidly, however they are not able to fulfill all the requirements of an epidemic reaction. Hence, to complement molecular diagnostic tests, serology tests emerged as a vital aspect of the overall response by confirming the presence of antibodies during the early stage of the infection. Antibody tests help in assessing herd immunity, data about the ongoing phase of infection, identifying potential donors for convalescent plasma therapy, etc. This review currently focuses on giving an overview about the antibody tests in SARS-CoV-2 infections. Wolters Kluwer - Medknow 2021-06 2021-06-05 /pmc/articles/PMC8375937/ /pubmed/34447041 http://dx.doi.org/10.4103/jpbs.JPBS_786_20 Text en Copyright: © 2021 Journal of Pharmacy and Bioallied Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Ravi, Arjun B.
Singh, V. P. Prabath
Chandran, Roshni
Venugopal, Krishnan
Haridas, Kaushik
Kavitha, R.
COVID-19 Antibody Tests: An Overview
title COVID-19 Antibody Tests: An Overview
title_full COVID-19 Antibody Tests: An Overview
title_fullStr COVID-19 Antibody Tests: An Overview
title_full_unstemmed COVID-19 Antibody Tests: An Overview
title_short COVID-19 Antibody Tests: An Overview
title_sort covid-19 antibody tests: an overview
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375937/
https://www.ncbi.nlm.nih.gov/pubmed/34447041
http://dx.doi.org/10.4103/jpbs.JPBS_786_20
work_keys_str_mv AT raviarjunb covid19antibodytestsanoverview
AT singhvpprabath covid19antibodytestsanoverview
AT chandranroshni covid19antibodytestsanoverview
AT venugopalkrishnan covid19antibodytestsanoverview
AT haridaskaushik covid19antibodytestsanoverview
AT kavithar covid19antibodytestsanoverview